CompletedPhase 2

Study of the Safety and Neuroprotective Capacity of Scp776 in Acute Ischemic Stroke

United States120 participantsStarted 2022-10-19

Plain-language summary

A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study of the Safety and Neuroprotective Capacity of Scp776 in Subjects Undergoing Endovascular Thrombectomy for Acute Ischemic Stroke

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Subject must be surgically sterile or be at least 1 year postmenopausal, OR
✓. Subjects of child-bearing potential must:
✓. have a monogamous partner who is surgically sterile.
✓. have a monogamous same sex partner.
✓. be practicing abstinence or using an acceptable form of birth control while participating in the study through Day 90. Site personnel will provide instructions on what is an acceptable method.

What they're measuring

Total number of SAEs recorded prior to hospital discharge

Timeframe: Baseline to Day 7 or at hospital discharge (whichever occurs first).

Proportion of subjects experiencing adverse events of special interest (AESIs)

Timeframe: Baseline to Day 7 or at hospital discharge (whichever occurs first).

Trial details

NCT IDNCT05585606

SponsorSilver Creek Pharmaceuticals

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-09-15

View on ClinicalTrials.gov More Acute Ischemic Stroke (AIS) trials